CMS SAYS IT HAS FINALIZED THE GLOBE MODEL TO DELIVER LOWER DRUG PRICES FOR BENEFICIARIES IN ORIGINAL MEDICARE PART B, WITH THE MODEL OPERATING FOR FIVE YEARS BEGINNING JANUARY 1, 2027 AND ENDING MARCH 31, 2032, THOUGH IT EXCLUDES BIOSIMILARS AND THEIR REFERENCE BIOLOGICALS ONCE A BIOSIMILAR ENTERS THE U.S. MARKET.